

Prange Pharma acquires MSD Animal Health Site in Aprilia, Italy to launch “Aprilia Animal Health”

Prange Pharma GmbH announced the signing of definitive agreements for the acquisition of MSD Animal Health’s manufacturing site in Aprilia, Italy. The formal transfer of ownership will be completed in the coming months.

After the sale closes, the site will be operated under “**Aprilia Animal Health**” and will be positioned as a dedicated center for contract manufacturing in the field of animal health products. The site’s portfolio will include both sterile and non-sterile manufacturing and filling, with capabilities covering beta-lactam antibiotics as well as specialized product categories such as ectoparasiticides. Prange Pharma GmbH is currently discussing the terms of a long-term supply partnership with MSD, to be signed upon Closing.

Otto Prange, Owner of Prange Group, commented:

“This acquisition marks a strategic step in strengthening our footprint in Europe and expanding our expertise in animal health manufacturing. We are fully committed to investing in the site, preserving jobs, and unlocking new opportunities for growth together with our partners. Aprilia Animal Health will play a pivotal role in our long-term strategy.”

Sebastian Heckerodt, Managing Director of Prange Pharma GmbH, added:

“We are excited to welcome the highly skilled team in Aprilia to Prange Pharma. Their know-how, dedication, and proven track record are the foundation for future success. Our ambition is to further develop Aprilia Animal Health into a center of excellence in contract manufacturing, while ensuring a seamless continuation of supply for P4SD and creating value for new customers.”

Angelo Gatto, Co-Shareholder, stated:

“Having spent many years in CDP4O for the Animal Health I am confident by saying that the industry will be welcoming Aprilia Animal Health with such broad capabilities and excellent team. In my role at Chanelle I am looking forward to rapidly cooperating on technologies which will be complementary.”

About Prange Pharma GmbH

Prange Pharma GmbH operates as an integral part of the owner-managed Prange Group, a prominent German family business with a proven track record of investing in and growing pharmaceutical companies and CDMOs. Through Prange Pharma, the group delivers contract development and manufacturing (CDMO) services across multiple sites.

Beyond CDMO operations, Prange Pharma supports a diverse portfolio of human and veterinary products - spanning OTC, Rx, medical devices, cosmetics; feed supplements and anti-parasitic solutions.

With Angelo Gatto joining as Co-Shareholder, his deep expertise in animal health strengthens Prange Pharma's strategic direction in this sector. His leadership will support the expansion of Aprilia Animal Health, driving innovation and excellence in contract manufacturing for veterinary pharmaceuticals.